Friends of Leronlimab

Friends of Leronlimab
An Emerging Therapeutic Drug for mTNBC, HIV

☰

Recent News From CytoDyn


View	December 2025 Letter to Shareholders
View	CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
View	CytoDyn Announces Resolution of Class Action Lawsuit
View	CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
View	CytoDyn Secures $30 Million Commitment from Yorkville Advisors
View	CytoDyn to Present at the LD Micro Main Event XIX Investor Conference
View	September 2025 Letter to Shareholders
View	CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
View	CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
View	CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

This is a private website & not associated with CYDY, Leronlimab, Vyrologix, CytoDyn or cytodyn.com All names, images & website links are the property of their respective owners.

This website is not giving any medical advice.
Do your own research.
Talk to your doctors.


Home	Menu


Privacy	Term of Service